XML 65 R52.htm IDEA: XBRL DOCUMENT v3.20.2
Related Party Transactions - Narrative (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Nov. 30, 2016
Mar. 31, 2016
Jan. 31, 2016
May 31, 2015
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2013
Dec. 31, 2010
Feb. 20, 2020
Dec. 31, 2019
Related-Party Transactions (Textual) [Abstract]                        
Revenue from related parties         $ 267,187 $ 135,673 $ 1,594,461 $ 2,965,579        
Long-term other assets         2,555,782   2,555,782         $ 2,672,024
Plumbline Life Sciences                        
Related-Party Transactions (Textual) [Abstract]                        
Revenue from related parties         64,000 40,000 1,200,000 64,000        
Accounts receivable         $ 13,000   $ 13,000         589,000
Plumbline Life Sciences | Available-for-sale Securities                        
Related-Party Transactions (Textual) [Abstract]                        
Investment owned (in shares)         597,808   597,808          
Investment owned, additional shares acquired (in shares)                     202,050  
GeneOne Life Sciences                        
Related-Party Transactions (Textual) [Abstract]                        
Investment owned (in shares)         1,644,155   1,644,155          
Payment received for license granted                   $ 3,000,000.0    
Term                 20 years      
Milestone-based ownership target     35.00% 35.00%                
Revenue from related parties         $ 31,000 31,000 $ 63,000 63,000        
Operating expenses related to affiliated entity         2,200,000 727,000 2,800,000 1,800,000        
Accounts receivable         3,000   3,000         128,000
Accounts payable and accrued liability         26,000   26,000         511,000
Long-term other assets         238,000   238,000         284,000
Director                        
Related-Party Transactions (Textual) [Abstract]                        
Term   5 years                    
Operating expenses related to affiliated entity         408,000 170,000 770,000 458,000        
Accounts receivable         370,000   370,000         616,000
Expenses to reimburse   $ 3,100,000                    
Awarded amount $ 6,100,000                      
Contra-research and development expense         73,000 $ 368,000 691,000 $ 1,200,000        
Accounts payable/accrued liabilities         486,000   486,000         $ 219,000
Deferred grant funding, from affiliate         $ 780,000   $ 780,000          
Plumbline Life Sciences                        
Related-Party Transactions (Textual) [Abstract]                        
Ownership percentage         19.90%   19.90%